November 18, 2025 — Leads & Copy —
Delcath Systems, Inc. (Nasdaq: DCTH) has announced the publication of a narrative review in the Journal of Vascular and Interventional Radiology (JVIR) highlighting the use of percutaneous hepatic perfusion (PHP) with melphalan, utilizing Delcath’s HEPZATO KIT™, for treating liver metastases from uveal melanoma (UM).
The review, titled “Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion,” consolidates data from prospective and retrospective studies across the U.S. and Europe, featuring insights from leading interventional radiologists and oncologists from multiple institutions.
Key findings from the review include objective response rates of 36%-72%, median overall survival of 15-20 months, and disease control rates up to 89%. The review emphasizes PHP’s suitability for multifocal, bilobar UM liver metastases, delivering high-dose chemotherapy with extracorporeal filtration to minimize systemic toxicity. It also notes the short-stay hospital admissions, typically with discharge within 24 hours, and advantages over other liver-directed therapies, such as a reduced risk of hepatic fibrosis compared to radioembolization in whole-liver treatments. Quality of life data indicated no long-term decline, with scores returning to baseline by Day 28 post-procedure.
The review also highlights ongoing research into immunotherapy combinations and the potential expansion of PHP to other metastatic cancers like breast and colorectal, aligning with Delcath’s efforts to advance interventional oncology.
According to Gerard Michel, Chief Executive Officer of Delcath Systems, the publication of this expert narrative review in JVIR highlights the growing clinical evidence and consensus supporting the use of PHP as a key treatment option for patients with liver-dominant metastatic uveal melanoma. Michel also stated that the review reinforces the value of HEPZATO KIT in achieving meaningful tumor responses and survival benefits while preserving quality of life, and that the company is encouraged by the highlighted potential for broader applications and combinations with systemic therapies.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Its products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System (HDS) for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.
HEPZATO KIT is FDA-approved as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
In Europe, the device-only configuration of the HDS is regulated as a Class Ill medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.
Contact:
Delcath Systems, Inc.
https://www.delcath.com/
Source: Delcath Systems, Inc.
